全部照片(1)
About This Item
經驗公式（希爾表示法）:
C20H24O2
CAS號碼:
分子量：:
296.40
MDL號碼:
分類程式碼代碼:
51111800
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D +250 to +300°, c = 1 in methanol
顏色
white to off-white
溶解度
DMSO: ≥20 mg/mL
儲存溫度
2-8°C
SMILES 字串
C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O
InChI
1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
InChI 密鑰
BFYIZQONLCFLEV-DAELLWKTSA-N
基因資訊
human ... CYP19A1(1588)
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.
特點和優勢
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
訊號詞
Danger
危險聲明
危險分類
Aquatic Chronic 2 - Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
Nan Soon Wong et al.
Expert opinion on pharmacotherapy, 6(13), 2353-2363 (2005-10-13)
Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients
Anneleen Lintermans et al.
Expert opinion on drug safety, 10(3), 473-487 (2011-03-25)
Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibitors. Exemestane is a third-generation aromatase inhibitor used in the treatment of estrogen-receptor-positive breast cancer
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
